Partnerships Cumberland Pharmaceuticals: Exclusive Joint Commercialization Agreement — U.S. commercialization via jointly controlled Talicia Holdings (RedHill 70% equity interest; profits shared equally). Gaelan Medical: UAE and Middle East commercialization
Indications
H. pylori infection in adults(Approved)
Status note First and only internally developed FDA-approved product. RedHill no longer directly commercializes Talicia; rights sold to Movantik sold separately.
RHB-102
Stage not disclosed · Active
Target 5-HT3
Partnerships Hyloris Pharmaceuticals (Feb 2025 exclusive license): responsible for development, manufacture, registration and commercialization in granted territories
Status note Out-licensed to Hyloris; this filing's extraction did not state indication or stage.
RHB-104
Stage not disclosed · Active
Indications
Crohn's disease(Stage not disclosed)
Status note Filing flags development/approval risk absent a validated MAP lab test; stage not stated in this excerpt.
RHB-204
Stage not disclosed · Active
Indications
Crohn's disease(Stage not disclosed)
Status note Stage not stated in this excerpt.
Per-asset detail extracted from the 20-F filed 2026-04-27. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
No lead program on file for this company.
No active ClinicalTrials.gov trials matched to this company as sponsor or collaborator.
No specialist-fund holders in 13F data for this company.
Get the weekly biotech catalyst rundown. Cash runways, financings, and trial readouts for all 714 stocks.